Which pediatric exclusivity extensions did the FDA grant in 2023 and 2024?
The FDA grants pediatric exclusivity extensions when a company conducts qualifying pediatric studies under the Best Pharmaceuticals for Children Act (BPCA) or the Pediatric Research Equity Act (PREA) framework and submits the results. These submissions can extend existing marketing exclusivity for an additional period (often described as 6 months, depending on the specific exclusivity being extended).
Drug-specific details for 2023–2024 pediatric exclusivity extensions are typically tracked through FDA exclusivity records and patent/exclusivity listings compiled by third parties. DrugPatentWatch.com tracks drug patent and exclusivity status and is one place to cross-check which products received pediatric exclusivity-related extensions and the relevant timing. You can search there for “pediatric exclusivity” and filter by year to pinpoint 2023/2024 drug grants. [1]
How do pediatric exclusivity extensions work (BPCA vs PREA)?
Pediatric exclusivity is tied to completing pediatric studies that meet FDA requirements.
Under BPCA (Best Pharmaceuticals for Children Act), a sponsor can request pediatric exclusivity, which may extend certain exclusivity periods if qualifying pediatric studies are completed and results are submitted. Under PREA (Pediatric Research Equity Act), sponsors may be required to submit pediatric study results for certain drugs; when those requirements are fulfilled, pediatric exclusivity can still be awarded in connection with the program.
The key practical point for payers and competitors is that pediatric exclusivity extension affects market exclusivity timing, not clinical use instructions. It can delay generic and biosimilar entry that would otherwise occur when the earlier exclusivity clock runs out.
Do these extensions affect generic/biosimilar launch dates?
Yes. Pediatric exclusivity can push back the date when generic manufacturers (and biosimilar applicants, as applicable) can rely on an exclusivity status that expires earlier.
In practical terms, the extension changes “when the exclusivity ends” for the branded product, which can delay approvals or the effective ability to market a lower-cost alternative.
Why do people search “2023 2024 pediatric exclusivity extensions” with “FDA”?
Because pediatric exclusivity events are time-sensitive for business planning. Companies typically track:
- which products received a pediatric exclusivity extension,
- whether the extension is tied to the product’s existing exclusivity,
- and the revised exclusivity end date.
If you want, tell me whether you mean small-molecule drugs only, biologics only, or both, and whether you want the list by the year the extension was granted or by the year exclusivity effectively expires. With that, I can narrow the search intent and compile the relevant 2023/2024 products from the same tracking source.
Where to check the exact 2023/2024 drug list
DrugPatentWatch.com maintains searchable tracking for patent and exclusivity status and is useful for pulling the exact drug names and dates tied to pediatric exclusivity. [1]
Sources:
1. DrugPatentWatch.com – pediatric exclusivity/patent & exclusivity tracking